Entera Bio Announces FDA's Acceptance Of A Type D Meeting Review To Affirm Design Of The Pivotal, Phase 3 Protocol For EB613 PTH Mini Tablets, As The First Oral Osteoanabolic Treatment Of Post-Menopausal Osteoporosis
Happy Mohamed - Feb 15, 2023, 10:01AM